Multidimensional Issues in Type 2 DiabetesDebates and Discussions Around Cardiovascular and Renal Outcomes
This activity is jointly provided by Global Education Group and Integritas Communications.
This activity is supported by an independent educational grant from AstraZeneca.
There is no registration fee for attending this program; however, seating is limited. Preregistration does not guarantee seating. We recommend arriving at the symposium location early.
The educational design of this activity addresses the needs of cardiology, endocrinology, and diabetology clinicians involved in the treatment of patients with type 2 diabetes.
Diabetes disorders afflict more than 30 million Americans, while another 84 million adult Americans have prediabetes.1 Multisystem consequences of type 2 diabetes mellitus (T2DM) include cardiovascular disease (CVD), heart failure (HF), and chronic kidney disease (CKD). The pathophysiologic mechanisms underlying T2DM, CVD, HF, and CKD share common characteristics: metabolic changes, a proinflammatory state, and oxidative stress.2 It is critical for providers to be aware of the heightened risk for poor outcomes in their patients with T2DM. Following several cardiovascular outcomes clinical trials with sodium-glucose cotransporter-2 (SGLT2) inhibitors, the American Diabetes Association recommends incorporating these agents (and other antihyperglycemic classes, such as glucagon-like peptide-1 receptor agonists), into treatment regimens for T2DM, particularly when CVD risks are elevated.3 The effects of SGLT2 inhibitors on renal glucose reabsorption, along with their ability to lower body weight, cardiac afterload, and blood pressure, translate to a reduction in renal and cardiac adverse events frequently associated with T2DM.4 The established relationships among T2DM, CVD, HF, and CKD necessitate individualized treatment to avoid or mitigate hyperglycemia and these common comorbidities. This live Clinical Issues™ program will address these topics to ensure attendees understand normal glucose homeostasis, the role of maladaptive reabsorption in T2DM, and the benefits SGLT2 inhibitors may have on common comorbidities associated with T2DM as well as their application in clinical practice.
- Centers for Disease Control and Prevention. National diabetes statistics report. 2017; https://www.cdc.gov/diabetes/data/statistics/statistics-report.html. Accessed November 15, 2018.
- Kovacic JC, Castellano JM, Farkouh ME, Fuster V. The relationships between cardiovascular disease and diabetes: focus on pathogenesis. Endocrinol Metab Clin North Am. 2014;43(1):41-57.
- Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669-2701.
- Toth-Manikowski S, Atta MG. Diabetic kidney disease: pathophysiology and therapeutic targets. J Diabetes Res. 2015;2015:697010.
After completing this activity, the participant should be better able to:
- Describe the reciprocal pathophysiologic relationships between T2DM and CVD, HF, and CKD, including treatment implications
- Compare the designs and results of large-scale cardiovascular outcomes trials with SGLT2 inhibitors for T2DM
- Discuss the mechanistic profiles, evidence for clinical benefits, and safety concerns associated with SGLT2 inhibitors as treatment options for patients with T2DM
- Intensify treatment regimens for patients with T2DM based on glycemic targets, cardiovascular and renal risks, recent guideline recommendations, and other clinical parameters
- 7:45PM–7:55PM Preactivity Questionnaire and Faculty Introductions
- 7:55PM–8:10PM Mechanistic Insights Into T2DM and Common Comorbidities
- 8:10PM–8:30PM Large-Scale Cardiovascular Outcomes Trials With SGLT2 Inhibitors
- 8:30PM–8:50PM Updates on Intensifying Therapy in T2DM
- 8:50PM–9:05PM Audience-Selected Case Studies
- 9:05PM–9:15PM Postactivity Questionnaire and Q&A Session
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.
*This CME/CE activity complies with all requirements of the federal Physician Payment Sunshine Act. If a reportable event is associated with this activity, the accredited provider managing the program will provide the appropriate physician data to the Open Payments database.
Physician Credit Designation
Global Education Group designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Global Education Group requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Americans with Disabilities Act
Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact Christa Master prior to the live event at (727) 637-2945 or firstname.lastname@example.org.
Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or email@example.com.